Diabetes Care Devices Market Size Projects USD 76.44 Billion by 2034
Ottawa, July 31, 2025 (GLOBE NEWSWIRE) -- The global diabetes care devices market size was valued at USD 33.58 billion in 2024 and is predicted to hit around USD 76.44 billion by 2034, a study published by Towards Healthcare a sister firm of Precedence Research.
Explore a preview of insights and trends shaping the Diabetes Care Devices Market: https://www.towardshealthcare.com/download-sample/5605
Key Takeaways
North America dominated the global diabetes care devices market in 2024.
Europe is anticipated to grow at the fastest rate in the market during the forecast period.
By monitoring devices, the glucometer device segment held the largest share of the self-monitoring blood glucose devices market in 2024.
By monitoring devices, the continuous blood glucose monitoring segment is estimated to grow at the fastest CAGR during the predicted timeframe.
By management devices, the disposable insulin pen segment held the largest share of the market in 2024.
By management devices, the insulin pump segment is predicted to grow at the highest CAGR in the market.
Market Overview & Potential
Diabetes care devices are medical tools that assist individuals in managing their diabetes by monitoring blood glucose levels, administering insulin, and offering other self-care support. These include continuous glucose monitors (CGMs), insulin pumps, smart insulin pens, and blood glucose meters. Their goal is to enhance glycemic control, lessen hypoglycemia risk, and improve the overall quality of life for people with diabetes.
What Drives the Growth of the Diabetes Care Devices Market?
The market is mainly fueled by the increasing number of diabetes cases, greater awareness of diabetes management, and technological advances in monitoring and treatment tools. Notably, the rising use of Continuous Glucose Monitoring (CGM) and Self-Monitoring of Blood Glucose (SMBG) devices, alongside the expansion of digital health and mobile apps for diabetes management, are key growth factors. CGM devices are becoming more popular because they offer real-time glucose data, helping users manage diabetes better and reduce complications.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
What Trends Are Shaping the Diabetes Care Devices Market?
Artificial Intelligence (AI):
• AI is increasingly integrated into diabetes devices to enhance glucose monitoring, foresee potential problems, and tailor treatments.
Smart Insulin Pens:
• Insulin pens with dose calculators are becoming widespread, removing guesswork from insulin administration.
Continuous Glucose Monitoring (CGM):
• CGM systems are gaining popularity, providing continual glucose tracking and enabling more personalized treatment.
Integration with Healthcare Providers:
• Devices with connectivity features allow easy sharing of data between patients and healthcare professionals, improving communication and coordinated care.
What Are the Main Challenges Facing the Diabetes Care Devices Market?
The market faces several challenges, including high device and treatment costs, strict regulatory requirements, and the need for ongoing technological innovation and diverse expertise. Additionally, access to these devices remains a concern in developing areas, and integrating digital health solutions can be complex. These factors limit the growth and also hinder the expansion of the market.
Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership
Regional
How Did North America Dominate the Diabetes Care Devices Market in 2024?
North America dominated the global diabetes care devices market in 2024. The growth of the market is driven by the growing demand for medical devices due to the high prevalence of diabetes, technological advancements, increased healthcare spending, a growing geriatric population, increased awareness, and early diagnosis, which increases the growth of the market in the region. The well-established companies like Abbott Laboratories, Medtronic, Roche Holding AG, and Johnson & Johnson also influence the growth due to their strong presence and strong healthcare infrastructure in the region.
Diabetes cases in the U.S. continue to rise, affecting over 38 million people. Sedentary lifestyles, unhealthy diets, and increasing obesity rates drive this trend. Type 2 diabetes is especially prevalent. Healthcare costs and complications strain public health systems. Prevention efforts focus on education, early detection, and lifestyle interventions.
Canada is witnessing a steady rise in diabetes, with over 3.7 million diagnosed cases. Type 2 diabetes dominates, linked to aging, obesity, and physical inactivity. Indigenous populations are disproportionately affected. Health agencies emphasize early intervention, public awareness, and improved access to nutritious foods and active living opportunities for prevention.
What made Europe Significantly Grow in The Diabetes Care Devices market in 2024?
Europe is anticipated to grow at the fastest rate in the market during the forecast period. The growth of the market is driven by the rising prevalence of diabetes in the region, with a growing number of patients, rising obesity and physical inactivity, technological advancements, government policies, and healthcare initiatives influencing the growth of the market in the region. The key players of the region, like Medtronic, Abbott, Roche, Dexcom, and LifeScan, also contribute to the growth through product innovation, strategic partnerships, and geographic expansion to attract consumers, which influences the growth and expansion of the market in the region.
Germany reports over 7 million people living with diabetes, primarily Type 2. The aging population, urban lifestyles, and increasing obesity contribute to the surge. Health authorities prioritize digital health tools, preventive care, and research. Public campaigns target better nutrition, physical activity, and early diagnosis to curb the disease's spread.
In the UK, diabetes affects nearly 5 million people, with numbers climbing steadily. Type 2 diabetes accounts for most cases, often linked to poor diet, inactivity, and obesity. The NHS is investing in prevention programs and digital support tools. Socioeconomic disparities also play a role in rising incidence rates.
According to Volza's Global Export data, the World shipped out 224 Glucose monitor shipments from October 2023 to September 2024 (TTM). These exports were handled by 46 global exporters to 59 buyers.
Globally, the United Kingdom, China, and Belgium are the top three exporters of Glucose monitors. The United Kingdom is the global leader in Glucose Monitor exports with 373 shipments, followed closely by China with 238 shipments, and Belgium in third place with 153 shipments.
Elevate your healthcare strategy with Towards Healthcare. Enhance efficiency and drive better outcomes schedule a call today: https://www.towardshealthcare.com/schedule-meeting
Segmental Insight
By Monitoring Devices
Which Monitoring Devices Segment Dominated the Diabetes Care Devices Market In 2024?
The glucometer device segment held the largest share of the self-monitoring blood glucose devices market in 2024. Glucometer devices are a vital component in diabetes management, which help individuals to self-monitor blood glucose levels with accuracy and convenience. These devices are especially prevalent in home-care settings due to their portability, cost-effectiveness, and ease of operation. Market growth is supported by the rising global diabetes burden, increased patient awareness, and expanding access in low- and middle-income regions. Despite the growing popularity of continuous glucose monitors (CGMs), glucometers continue to dominate in affordability-sensitive markets. Technological advancements such as Bluetooth connectivity, smartphone integration, and no-coding strips are enhancing user experience, ensuring the segment remains relevant in a rapidly evolving diabetes care landscape.
The continuous blood glucose monitoring segment is estimated to grow at the fastest CAGR in the diabetes care devices market during the predicted timeframe. Continuous blood glucose monitoring (CGM) devices have revolutionized diabetes care by offering real-time, continuous tracking of glucose levels throughout the day and night. These devices eliminate the need for frequent finger-prick tests, providing users with detailed glucose trends and alerts for hypo- or hyperglycemia. Market growth is driven by rising type 1 and type 2 diabetes cases, increased adoption in health and wellness applications, and technological innovations like smartphone integration and predictive analytics. Key players such as Dexcom, Abbott, and Medtronic lead the segment, with expanding usage across both clinical and personal settings globally, enhancing its future outlook.
By Management Devices
How did Segment dominate the Diabetes Care Devices Market in 2024?
The disposable insulin pen segment held the largest share of the market in 2024. Disposable insulin pens are prefilled, single-use devices designed to deliver accurate insulin doses conveniently and safely. These pens are user-friendly, making them ideal for patients with limited dexterity or those new to insulin therapy. Market demand is rising due to the increasing prevalence of diabetes, especially type 2, and growing patient preference for portable and discreet insulin delivery options. Their ease of use reduces dosing errors and enhances treatment adherence. The segment is witnessing steady growth across both developed and emerging markets, supported by ongoing product innovations, rising awareness, and favorable reimbursement policies promoting at-home diabetes management.
The insulin pump segment is predicted to grow at the highest CAGR in the diabetes care devices market. Insulin pumps are advanced diabetes management devices that deliver continuous subcutaneous insulin infusion, closely mimicking the body's natural insulin release. These devices offer greater flexibility in insulin dosing, improved glycemic control, and reduced risk of hypoglycemia, especially for Type 1 diabetic patients. The market is growing due to technological advancements like patch pumps, integration with CGMs, and smart algorithms enabling automated insulin delivery. High adoption in developed regions, along with rising awareness and clinical recommendations, is further boosting demand.
Recent Developments
In February 2025, the UVA Center for Diabetes Technology launched a trial to test AI AI-powered device for diabetes management amid rising cases of diabetes. For management by testing an innovative AI-powered device is being tested to improve automated insulin delivery.
In November 2024, Singapore launched a new telehealth platform for diabetes management with real-time monitoring and for providing timely treatment.
Top Companies and Their Contributions to the Diabetes Care Devices Market
Company
Contributions & Offerings
Medtronic plc
Medtronic leads in insulin delivery systems such as MiniMed pumps and closed-loop Automated Insulin Delivery systems. It recently received FDA clearance for its Simplera Sync sensor integrated with its pump ecosystem. Its diabetes segment sales rose sharply thanks to the adoption of MiniMed 780G and Simplera. Medtronic emphasizes interoperability and partnerships to build integrated CGM-pump systems.
Abbott Laboratories
Abbott offers the FreeStyle Libre Flash and CGM systems (Libre, Libre 2, Libre 3), plus Lingo consumer monitors, apps LibreLink, LibreView, and LibreLinkUp. Libre is used by millions, widely reimbursed, and integrated into insulin delivery via partnerships including Medtronic. CGM sales surged by over 21 percent, making Abbott a market leader.
F. Hoffmann-La Roche Ltd.
Roche Diabetes Care develops blood glucose meters, test strips, and CGMs such as the Accu-Chek portfolio. Offers professional systems used in clinics and integrated digital platforms. Focused on accuracy, point-of-care solutions, and global reimbursement adoption. (Note: contributions based on industry leader reports)
Bayer AG
Bayer offers diabetes diagnostics (blood glucose monitors) and test strips under Bayer Diabetes Care. It supports insulin dose advisors and data management solutions. It invests in research on automated insulin dosing analytics.
LifeScan, Inc.
LifeScan produces OneTouch blood glucose monitoring systems, including meters, test strips, and data platforms. It's OneTouch Verio Flex and OneTouch Reveal app support user engagement and data analysis.
B. Braun Melsungen AG
B. Braun provides insulin infusion pump systems, infusion sets, and infusion therapy solutions. Their pumps integrate with glucose monitoring and hospital insulin delivery workflows, emphasizing safety and precision.
Dexcom Inc.
Dexcom develops continuous glucose monitors, G6, G7, and the low-cost Stelo device. G-series supports interoperability with Tandem and Insulet pumps, enabling closed-loop systems. Dexcom Clarity software allows data to be analyzed and enables remote monitoring.
Insulet Corporation
Insulet manufactures tubeless patch insulin pumps, including the Omnipod DASH and Omnipod 5. Omnipod 5 is FDA-cleared automated insulin delivery pumping every five minutes, integrated with Dexcom G6, G7, and Libre 2 Plus. It targets Type 1 and expanding Type 2 populations.
Ypsomed Holdings
Ypsomed offers the mylife YpsoPump, an insulin pump compatible with the Dexcom G6 CGM in closed-loop operation, under a partnership. It serves European markets, focusing on patient choice and flexible integration.
Browse More Insights of Towards Healthcare:
The diabetes management technologies market is on track for strong growth by 2034, driven by continuous innovation in glucose monitoring devices, insulin delivery systems, and digital health platforms that are improving patient outcomes.
The disposable diabetes lancets market was valued at around USD 1.19 billion in 2023 and is expected to reach USD 1.9 billion by 2034, growing steadily at a CAGR of 4.33% from 2024 onwards.
The safety lancets market is also seeing rapid expansion estimated at USD 2.1 billion in 2023, it's projected to grow to USD 6.32 billion by 2034, thanks to a robust CAGR of 10.54%.
The global chronic disease treatment market is accelerating. Starting at USD 8.37 billion in 2024, it's forecasted to climb to USD 9.74 billion by 2025 and reach nearly USD 38.02 billion by 2034, driven by a strong CAGR of 16.34%.
The global market for diabetes drugs is projected to grow from USD 75.16 billion in 2025 to USD 134.73 billion by 2034, expanding at a healthy CAGR of 6.7% over the next decade.
The pacemaker market is gradually increasing in value worth USD 5.45 billion in 2024, rising to USD 5.66 billion in 2025, and expected to reach USD 7.89 billion by 2034 with a CAGR of 3.75%.
The hernia mesh device market size is forecasted to increase from USD 5.63 billion in 2024 to USD 6.02 billion in 2025 and hit around USD 11.01 billion by 2034, growing at a CAGR of 6.94%.
The life sciences enterprise storage market is also showing upward momentum. It's expected to grow from USD 2.71 billion in 2024 to USD 2.86 billion in 2025, reaching approximately USD 4.67 billion by 2034, with a CAGR of 5.65%.
Pain management devices are gaining traction globally, with the market valued at USD 7.68 billion in 2024 and forecasted to grow to USD 8.41 billion in 2025, ultimately reaching USD 19.1 billion by 2034, reflecting a CAGR of 9.54%.
The connected drug delivery devices market is experiencing remarkable growth. From USD 7.44 billion in 2024 and USD 9.18 billion in 2025, it's set to soar to USD 61.08 billion by 2034, growing at an impressive CAGR of 23.44%.
Key Players in the Diabetes Care Devices Market
Medtronic plc
Abbott Laboratories
F.Hoffmann-La-Ltd.
Bayer AG
B Braun Melsungen AG
Lifescan, Inc.
Dexcom Inc.
Insulet Corporation
Ypsomed Holdings
Companion
Medical
Sanofi
Valeritas Holding Inc.
Novo Nordisk
Arkray, Inc
Segments Covered in The Report
By Region
North America
U.S.
Canada
Asia Pacific
China
Japan
India
South Korea
Thailand
Europe
Germany
UK
France
Italy
Spain
Sweden
Denmark
Norway
Latin America
Brazil
Mexico
Argentina
Middle East and Africa (MEA)
South Africa
UAE
Saudi Arabia
Kuwait
To invest in our premium strategic solution and customized market report options, click here: https://www.towardshealthcare.com/price/5605
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Gain access to the latest insights and statistics in the healthcare industry by subscribing to our Annual Membership. Stay updated on healthcare industry segmentation with detailed reports, market trends, and expert analysis tailored to your needs. Stay ahead of the curve with valuable resources and strategic recommendations. Join today to unlock a wealth of knowledge and opportunities in the dynamic world of healthcare: Get a Subscription
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
Our Trusted Data Partners
Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire
Find us on social platforms: LinkedIn | Twitter | Instagram
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
12 minutes ago
- Washington Post
A Danish zoo is seeking unwanted pets — to feed to its predators
A zoo in Denmark has put out a call for people to donate unwanted pets and animals — including chickens, rabbits and guinea pigs — so they can be turned into feed for its predators. Aalborg Zoo wrote on social media last week that healthy animals it receives will be 'gently euthanized' by trained staff and then used as food for the predators, adding that this would help the zoo replicate its animals' natural food chain. 'That way, nothing goes to waste — and we ensure natural behavior, nutrition and well-being of our predators,' the zoo said, adding that some of its animals needed to eat 'whole' prey. The zoo also accepts donations of certain horses, which are also euthanized and then used as food. Online, critics balked at the idea of pets being fed to zoo animals, calling it a 'cheap publicity stunt,' 'disrespectful' and 'sick,' and a policy they say could encourage pet neglect. However, others said it was a good option for people whose pets are nearing the end of their lives and a way to make sure their deaths serve a purpose. Experts say donation can be a more cost-effective and natural way of feeding zoo animals who might otherwise be fed meat from commercial sources that can come from animals raised in poor conditions. 'If you agree to the general principle that you have carnivorous animals in a zoo, you somehow succumb to the necessity that you have to feed them animal material,' Marcus Clauss, co-director of the Clinic for Zoo Animals, Exotic Pets and Wildlife at the University of Zurich, said in an interview. 'If you do this in a way that is not primarily directed at economics, but at animal welfare, you will strive to get animals that had high welfare, ideally.' Aalborg Zoo did not immediately respond to a request for comment Tuesday. In a statement shared with the outlet Popular Science, spokeswoman Pia Nielsen said the practice of feeding carnivorous animals with smaller livestock has been used at Aalborg Zoo for many years and is common in Denmark. 'When keeping carnivores, it is necessary to provide them with meat, preferably with fur, bones, etc., to give them as natural a diet as possible. Therefore, it makes sense to allow animals that need to be euthanized for various reasons to be of use in this way,' Nielsen told Popular Science. 'In Denmark, this practice is common, and many of our guests and partners appreciate the opportunity to contribute.' Zoos in other countries also accept donations of livestock, or deceased animals, to feed their predators. The Wild Spirit Wolf Sanctuary in New Mexico, for example, states on its website that it accepts donations of 'livestock that has passed away or needs to be humanely euthanized' to feed its wolves and recommends donation over 'having to dispose of the deceased in a landfill, or go through the costly process of cremation.' The Alaska Zoo in Anchorage recently put out a call for frozen meat and fish donations for its animals. Clauss said that when horses are slaughtered, 'you have a huge amount of animal — meat, bones, etc. — that goes to waste in our system because it's not used by humans.' He said he supports zoos offering people the option of donating their horses if the alternative is that zoos purchase horsemeat to feed their carnivores. 'Why not get it that way directly?' Clauss acknowledged concerns that encouraging people to donate animals might mean fewer unwanted pets are placed in shelters. But he said pet shelters in many countries, including the United States, are overcrowded and can't always ensure optimal conditions for the pets in their care, so that option might not guarantee a higher welfare for the unwanted animals. And he said that forcing someone who doesn't want or can't afford their pet to keep them may also not be good for the animal. 'People who want to get rid of their animals will find a way of doing that,' he said. In response to the call for donations by the Aalborg Zoo, several Facebook users wrote that they took their horses to be donated there and praised the zoo's handling of their animals, while others wrote that they were planning to donate their horses in the future. It was not immediately clear how the donated animals would be euthanized. On Facebook, the zoo said trained professionals worked to make the deaths as quick and painless as possible.
Yahoo
39 minutes ago
- Yahoo
Digital health company eMed taps former X boss Linda Yaccarino as CEO
(Reuters) - Digital health platform eMed Population Health said on Tuesday it has appointed Linda Yaccarino, the former CEO of social media site X, as its chief executive officer. The online weight management company's digital platform provides at-home diagnostics, proctor-led screenings, physician-guided prescribing for patients with obesity and type 2 diabetes. Yaccarino, one of Elon Musk's top deputies, stepped down from her role at the social media site in July, in a surprise move just months after the platform was acquired by the billionaire's AI startup, xAI.
Yahoo
39 minutes ago
- Yahoo
Annual spending on specialty drugs continues to increase but at a slower pace than prior years, driven in part by biosimilar adoption.
DALLAS, August 05, 2025--(BUSINESS WIRE)--Pharmaceutical Strategies Group ("PSG"), an EPIC company, released the Artemetrx State of Specialty Spend and Trend report. This annual report provides a comprehensive analysis based on real world data of utilization of specialty medications across both pharmacy and medical benefits. This year's report revealed per member per year specialty drug cost increased from $1,333 in 2023 to $1,641 in 2024. However, specialty drug trend decreased to 9.6% in 2024 on a gross cost basis, a decline from 14.4% in 2023. Notably, cost per claim was meaningfully less of a contributor to trend this year versus recent years. "The data reveals a compelling story regarding what is happening with specialty drugs. Overall costs continue to increase for healthcare payers, but what is driving that cost is changing," stated Morgan Lee, PhD, Senior Director of Research & Strategy at PSG. "Adoption of Humira biosimilars helped pull specialty trend down this year, which is evident throughout the report," Lee added. While Humira continued its multi-year reign as the top specialty drug in terms of overall spend, this popular drug experienced negative utilization and cost per claim trends driven by the adoption of biosimilars. "In 2024, we saw the benefit to healthcare payers of Humira biosimilars as PBMs shifted strategies to take advantage of competition in the market," observed Renee Rayburg, RPh, Vice President of Clinical Strategy at PSG. "We expect to see faster adoption of Stelara biosimilars, which entered the market early this year. However, we're also seeing a push to move patients from these drugs to other brand drugs that do not have biosimilar competition." The Artemetrx State of Specialty Spend and Trend Report reflects PSG's commitment to providing data-driven insights regarding the management of and opportunities to optimize specialty medications. The complimentary report can be downloaded here. Additional findings covered in the report include: The percentage of members utilizing a specialty drug increased (4.7%), while average specialty claims per utilizer was steady (5.9) The shift of specialty drug spending to the pharmacy benefit continued The top three categories for specialty drug spend remained unchanged: Inflammatory Disorder, Oncology, Multiple Sclerosis PSG will host a webinar on August 13th, at 1:00 ET to discuss how this report can shape a roadmap for proactive specialty spend control. Registration is available online. About Pharmaceutical Strategies Group (PSG) Pharmaceutical Strategies Group, an EPIC company, relentlessly advocates for clients as they navigate complex and ever-changing drug cost management challenges. PSG is an independent consultant, empowering healthcare payers to optimize their pharmacy program. As a strategic partner, PSG helps clients by providing industry-leading intelligence and technologies to realize billions of dollars in drug cost savings for clients every year. About Artemetrx® Artemetrx is a proprietary SaaS platform developed by Pharmaceutical Strategies Group, an EPIC company. As a revolutionary technology solution integrating pharmacy and medical claims data for specialty drug cost management, Artemetrx provides market-leading specialty drug insights to payers. It delivers unparalleled intelligence and line-of-sight into serious challenges perpetuating out-of-control drug costs and compromised patient outcomes. PSG's innovative drug management solutions, including Artemetrx, deliver actionable insights with exceptional financial and clinical value. PSG functions as a strategic partner through industry-leading intelligence and technologies to realize billions of dollars in drug cost savings for clients every year. View source version on Contacts Artemetrx Business Development Travis Media Contact Gregory FCA For Pharmaceutical Strategies GroupKara Lesterepic@ Sign in to access your portfolio
